ARTICLE | Company News
Xoma, Allergan deal
November 20, 2000 8:00 AM UTC
AGN terminated a 1999 agreement under which it had an exclusive license to develop products based on XOMA's rBPI (recombinant bactericidal/permeability-increasing protein) to treat bacterial eye infec...